4-Chloro-6,8-Difluoroquinoline

4-Chloro-6,8-Difluoroquinoline

SCHEMBL264453

Fc1cc(F)c2nccc(Cl)c2c1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CDK9 P50750 1/20 0.43
CDK5 Q00535 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 5/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
LMNA P02545 3/20 0.37
HSP90AA1 P07900 3/20 0.37
MMP14 P50281 3/20 0.37
TP53 P04637 2/20 0.37
CYP3A4 P08684 2/20 0.37
ALOX15 P16050 2/20 0.37
ALOX12 P18054 2/20 0.37
SLC6A2 P23975 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Chloro-6,8-Difluoroquinoline SCHEMBL30225421 1.00 CDK8 (0.43) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL6537590 0.81 NR4A2 (0.43) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL20293018 0.81 KDM4E (0.35) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL24009363 0.78 PDE2A (0.42) KDM4EMAPTTDP1LMNAHSP90AA1
SCHEMBL20293046 0.78 EGFR (0.38) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL3254363 0.77 CDK8 (0.43) CDK8GSK3AGSK3BCDK9CDK5
6,8-Difluoroquinolin-4(1H)-One SCHEMBL2207039 0.77 CDK8 (0.46) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL20277757 0.77 CDK8 (0.43) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL5260883 0.77 CDK8 (0.43) CDK8GSK3AGSK3BCDK9CDK5
SCHEMBL13577838 0.77 CCR1 (0.52) CDK8GSK3AGSK3BCDK9CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137177-A2 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2009-12-30 EP claimed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 WO claimed
US-20250188053-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES REATA PHARMACEUTICALS, INC. (US) 2025-06-12 US disclosed
CN-110248932-B Pyrimidine tricycloalkenone derivatives for ROR γ inhibition and other uses 里亚塔医药公司 2023-03-10 CN disclosed
US-20220135534-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES REATA PHARMACEUTICALS, INC. (US) 2022-05-05 US disclosed
US-11292781-B2 Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses REATA PHARMACEUTICALS, INC. (US) 2022-04-05 US disclosed
US-11066392-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-20 US disclosed
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2020-11-12 US disclosed
US-20200131148-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES REATA PHARMACEUTICALS, INC. (US) 2020-04-30 US disclosed
US-20200095231-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE BRISTOL-MYERS SQUIBB COMPANY 2020-03-26 US disclosed
EP-3555062-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR GAMMA AND OTHER USES Reata Pharmaceuticals, Inc. (US) 2019-10-23 EP disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
EP-2137177-A2 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2009-12-30 EP disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
EP-2044018-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS Pfizer Japan, Inc. (JP) 2009-04-08 EP disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 WO disclosed
WO-2008007211-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-01-17 WO disclosed
EP-1724268-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-22 EP disclosed
WO-2000047576-A1 CINNAMIDE DERIVATIVES AS OREXIN-1 RECEPTORS ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT CDK8 1163/4885GSK3A 170/4885GSK3B 179/4885
US-20090069297-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 CDK8 6/4885GSK3A 138/4885GSK3B 146/4885
US-20220135534-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES RORC, RORB, RORA CDK8 419/4885GSK3A 465/4885GSK3B 329/4885
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 CDK8 2648/4885GSK3A 3506/4885GSK3B 3690/4885
US-11066392-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use IDO1, IDO2, INMT CDK8 143/4885GSK3A 86/4885GSK3B 62/4885
US-20250188053-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES RORC, RORB, RORA CDK8 419/4885GSK3A 465/4885GSK3B 329/4885
US-20200095231-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE IDO1, IDO2, INMT CDK8 143/4885GSK3A 86/4885GSK3B 62/4885
US-11292781-B2 Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses RORC, RORB, RORA CDK8 419/4885GSK3A 465/4885GSK3B 329/4885
US-20200131148-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES RORC, RORB, RORA CDK8 419/4885GSK3A 465/4885GSK3B 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.